# A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

> **NCT05298683** · PHASE2 · UNKNOWN · sponsor: **Hellenic Society of Hematology** · enrollment: 108 (estimated)

## Conditions studied

- Multiple Myeloma
- Renal Impairment
- Neoplasms, Plasma Cell
- Neoplasms by Histologic Type
- Neoplasms
- Paraproteinemias
- Blood Protein Disorders
- Hematologic Diseases

## Interventions

- **DRUG:** Isatuximab
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Acetaminophen (paracetamol)
- **DRUG:** Ranitidine (or equivalent)
- **DRUG:** Diphenhydramine (or equivalent)

## Key facts

- **NCT ID:** NCT05298683
- **Lead sponsor:** Hellenic Society of Hematology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05
- **Primary completion:** 2025-11
- **Final completion:** 2026-01
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2022-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05298683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05298683, "A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor". Retrieved via AI Analytics 2026-06-21 from https://api.ai-analytics.org/clinical/NCT05298683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*